The Efficacy of Acamprosate in Enhancing Abstinence in Alcohol Dependence: A Meta-Analysis Evaluating Continuous and Controlled Abstinence, Women and Alcoholism: An Individual Patient Data (IPD) Meta-Analysis of Outcome Predictors Based on 935 Female Pati

Lehert, Philippe;Landron, F;Tourkodimitris, S;Schneider, E
(2006) American Society of Addiction ASAM’s 38th Annual Medical Scientific Conference April 26-29, 2006 T — Location: Miami ,USA

Files

No attached file found for this publication.

Details

Authors
  • Lehert, Philippeorcid-logoFUCaM
    Author
  • Landron, F
    Author
  • Tourkodimitris, S
    Author
  • Schneider, E
    Author
Abstract
(en) Acamprosate is an FDA-approved medication that enhances abstinence in alcohol-dependent patients. A meta-analysis was carried out to compare acamprosate with placebo on TA and CA. 21 randomized, placebo-controlled trials (RCTs) that fulfilled predetermined selection criteria were identified. Primary outcome measures were percent days of TA (defined as zero drinks during the treatment interval) and CA (defined as <5 standard drinks/day during the treatment interval). TA and CA rates were also significantly higher with patients treated with acamprosate vs. placebo (40.5% vs. 27.2%; RR, 0.653; 95% CI, .569-.749; P<.001) with an NNT=6.8. Acamprosate can provide a significant benefit by reducing alcohol consumption during relapse.
Affiliations
  • Louvain School of Management

Citations

  • APA
  • Chicago
  • FWB

Lehert, P., Landron, F., Tourkodimitris, S., & Schneider, E. (2006). The Efficacy of Acamprosate in Enhancing Abstinence in Alcohol Dependence: A Meta-Analysis Evaluating Continuous and Controlled Abstinence, Women and Alcoholism: An Individual Patient Data (IPD) Meta-Analysis of Outcome Predictors Based on 935 Female Pati. American Society of Addiction ASAM’s 38th Annual Medical Scientific Conference April 26-29, 2006 T, Miami ,USA. https://hdl.handle.net/2078.5/129912